New allergy shot aims to tame mugwort season in just four weeks
NCT ID NCT07563439
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This Phase 2 trial tests PollenVax, a new immunotherapy for people with moderate-to-severe allergic rhinitis caused by mugwort pollen. The treatment is given as four weekly shots before the pollen season. Researchers will compare symptom scores and medication use between the PollenVax groups and a placebo group. The goal is to see if this ultra-short regimen can safely ease seasonal allergy symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PollenVax (recombinant mugwort allergen Art v 1 with adjuvant Montanide ISA-51)
What this could lead to
If successful, this could lead to a convenient, ultra-short treatment course that reduces allergic rhinitis symptoms and the need for daily allergy medications during mugwort pollen season.
What could go wrong
This is an early Phase 2 trial with only 138 participants, so results may not apply to everyone. The treatment may cause injection site reactions or fail to outperform placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINITIS ALLERGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Limited Liability Partnership "Medcenter-Rakhat"
RECRUITINGAlmaty, Almaty, 050010, Kazakhstan
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact